Sermorelin/Ipamorelin Injection - $290.00 / month for 12 months
Sermorelin/Ipamorelin is a combination of two peptides which together cause a more effective stimulation of growth hormone production and release than alone.
Sermorelin, a growth hormone releasing hormone (GHRH), is a safe and effective peptide that stimulates the production and release of your own natural growth hormone from your pituitary gland. This peptide, taken at bedtime, teases out your own growth hormone during sleep to complement your natural biological rhythm.
Ipamorelin, a growth hormone secretagogue, increases growth hormone production and release differently than Sermorelin by mimicking the gastric hormone, ghrelin. Ipamorelin stimulates the production and release of growth hormone by binding to ghrelin receptors located on the pituitary gland.
Research & Benefits
In multiple research studies, peptides have been shown to increase growth hormone levels resulting in countless health benefits. One study, on the peptide Sermorelin, showed that over a 6 month period, both men and women experienced a decrease in body fat and increase in lean body mass. In another study, IGF-1 levels increased by 30% in men and 23% in women. IGF-1 (Insulin-like growth factor-1), is a hormone produced in response to growth hormone stimulation, therefore when growth hormone levels are elevated, so are IGF-1 levels. Studies on long term use are ongoing, but so far the consensus is that they are safe, effective, and well tolerated for the uses of anti-aging.
How to Use
The most common way to take Sermorelin/Ipamorelin is by subcutaneous injection, which is directly under the skin into the fat. These injections are taken at bedtime as they work better with the body's natural biological rhythm of growth hormone secretion during sleep.
Very few side effects are associated with the use of Sermorelin/Ipamorelin as they work with the body's natural ability of producing and releasing growth hormone. Some of the following side effects may occur in less than 1% of patients.
A large proportion of patients develop anti- GRF antibodies at least once during treatment with Sermorelin. The significance of these antibodies is not clear, and the presence of antibodies does not appear to affect growth or appear to be related to a specific adverse reaction profile. No generalized allergic reactions to Sermorelin have been reported.
The most common treatment-related adverse event (occurring in about 1 patient in 6) is local injection reaction characterized by pain, swelling or redness. Of 350 patients exposed to Sermorelin in clinical trials, three discontinued therapy due to injection reactions. Other treatment-related adverse events had individual occurrence rates of less than 1% and include: headache, flushing, dysphagia (swallowing difficulties), dizziness, hyperactivity, somnolence (sleepiness, drowsiness) and urticaria (itching).
Untreated hypothyroidism (underactive thyroid) can decrease the effectiveness of Sermorelin. It’s recommended that those interested in peptides get their thyroid hormones checked before starting treatment.
- Facial Flushing
- Injection site pain, swelling, or redness
- Increased appetite
- Sleepiness or Drowsiness
- Uticaria (itching)
- Dysphagia (swallowing difficulty)